Literature DB >> 3209762

Cutaneous IgA subclasses in dermatitis herpetiformis and linear IgA disease.

F Wojnarowska1, D Delacroix, P Gengoux.   

Abstract

The subclasses of the cutaneous IgA were studied in 8 patients with dermatitis herpetiformis and 4 with linear IgA disease. The cutaneous IgA in dermatitis herpetiformis consisted of both IgA1 and IgA2, although IgA1 predominated. This demonstrated that the IgA is polyclonal and may be both mucosal and blood derived. The IgA in linear IgA disease was exclusively IgA1, confirming previous work, and suggesting that mucosal IgA may not make a major contribution to the skin deposits.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3209762     DOI: 10.1111/j.1600-0560.1988.tb00558.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  4 in total

1.  Association between levels of IgA antibodies to tissue transglutaminase and gliadin-related nonapeptides in dermatitis herpetiformis.

Authors:  Justyna Gornowicz-Porowska; Monika Bowszyc-Dmochowska; Agnieszka Seraszek-Jaros; Elżbieta Kaczmarek; Marian Dmochowski
Journal:  ScientificWorldJournal       Date:  2012-04-01

2.  Granular Deposits of IgA in the Skin of Coeliac Patients Without Dermatitis Herpetiformis: A Prospective Multicentric Analysis.

Authors:  Emiliano Antiga; Roberto Maglie; Gabriele Lami; Alessandro Tozzi; Veronica Bonciolini; Francesca Calella; Beatrice Bianchi; Elena Del Bianco; Daniela Renzi; Edoardo Mazzarese; Antonino S Calabrò; Marzia Caproni
Journal:  Acta Derm Venereol       Date:  2021-02-02       Impact factor: 3.875

Review 3.  Missing Insight Into T and B Cell Responses in Dermatitis Herpetiformis.

Authors:  Esko Kemppainen; Teea Salmi; Katri Lindfors
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

Review 4.  Antibody Responses to Transglutaminase 3 in Dermatitis Herpetiformis: Lessons from Celiac Disease.

Authors:  Helka Kaunisto; Teea Salmi; Katri Lindfors; Esko Kemppainen
Journal:  Int J Mol Sci       Date:  2022-03-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.